Conventional Treatments for Raynaud's Syndrome Explained: What Doctors Actually Prescribe

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.

There Are Zero FDA-Approved Drugs for Raynaud's — Here's What Doctors Prescribe Instead

A 2025 study from researchers at Vanderbilt and Tufts, published in Arthritis Care & Research, confirmed something many Raynaud's patients already suspected: there are zero FDA-approved therapies for Raynaud's phenomenon (RP) in the United States. Every medication currently prescribed for this condition was originally developed for something else and is used off-label. This is the clinical reality, not a fringe claim.

That reality is especially striking given how common Raynaud's actually is. A 2024 umbrella review of systematic reviews found a global pooled prevalence of 4.85%, and estimates suggest that 20% to 30% of women in cooler climates may be affected. Yet the pharmaceutical treatment pipeline remains essentially empty.

Understanding the two forms of RP helps clarify why treatment approaches differ. Primary Raynaud's accounts for 80% to 90% of all cases and occurs without an underlying disease. Secondary Raynaud's is linked to autoimmune conditions like scleroderma, where RP appears in over 95% of patients.

If you've been managing Raynaud's quietly, you're not alone. Only about 32% of RP patients ever see a doctor about their symptoms. This article maps the full conventional treatment spectrum honestly, including its very real limitations.

Step One: Lifestyle Modifications as First-Line Care

Clinical guidelines from the American College of Rheumatology and other bodies universally place lifestyle changes before any medication. This is not a placeholder recommendation while you wait for "real" treatment. It is evidence-based first-line care.

The specifics matter. Avoiding cold exposure is foundational, but it goes beyond wearing gloves. Keeping your core body temperature warm is critical because your body restricts blood flow to extremities when your core cools. Layering with insulated gloves, warm socks, and a good base layer can make a meaningful difference. Chemical hand warmers are a practical tool, not a luxury.

Stress reduction is equally important. Emotional stress can provoke vasospasm just as effectively as cold temperatures. Deep breathing, meditation, or simply identifying and reducing stress triggers can help manage attack frequency.

If you smoke, quitting is one of the most impactful changes you can make. Nicotine causes vasoconstriction and directly worsens RP attacks. Regular aerobic exercise also improves baseline circulation and vascular tone over time, making blood vessels more responsive and resilient.

For many people with primary Raynaud's, these measures alone may be enough. A 2025 prospective study found remission rates as high as 64% in primary RP patients. For secondary Raynaud's, lifestyle modifications are recommended alongside medications, not as a substitute for them.

First-Line Medications: Calcium Channel Blockers

When lifestyle changes aren't sufficient, the most widely prescribed pharmacological treatment for Raynaud's syndrome is a class of drugs called dihydropyridine calcium channel blockers (CCBs). Nifedipine is the customary first choice, typically prescribed as an extended-release tablet at doses ranging from 30 to 120 mg daily.

CCBs work by relaxing the smooth muscle in blood vessel walls, allowing vessels to widen and reducing both the frequency and severity of vasospastic attacks. EULAR (European Alliance of Associations for Rheumatology) guidelines formally recommend dihydropyridine CCBs as first-line pharmacological therapy, particularly for secondary RP related to scleroderma.

Transparency about side effects matters here. CCBs commonly cause headaches, facial flushing, and ankle swelling. More critically, they can cause hypotension (low blood pressure). This creates a significant clinical gap: vasodilators, including CCBs, are contraindicated or limited in patients who already have low blood pressure. Because low blood pressure is a common comorbidity in RP patients, a meaningful subset of people simply cannot tolerate the most recommended medication.

It's also worth understanding what CCBs don't do. They may reduce the frequency of attacks, but they do not address the underlying vascular dysfunction that causes Raynaud's. The root problem remains. For many patients, this means ongoing management rather than resolution.

Second-Line Medications: When CCBs Aren't Enough

When calcium channel blockers fail or aren't tolerated, doctors turn to a range of second-line options. All of these are off-label uses, and none are FDA-approved for Raynaud's specifically.

• PDE-5 inhibitors (e.g., sildenafil): Originally developed for pulmonary hypertension and erectile dysfunction, these drugs are now used off-label for RP. EULAR guidelines list them as a second-line option.
• Prostaglandin analogs (e.g., iloprost IV): Reserved for severe secondary RP with digital ulcers. Intravenous administration limits accessibility for most patients.
• Angiotensin receptor blockers (e.g., losartan): Primarily a blood pressure medication, repurposed for RP with modest supporting evidence.
• SSRIs (e.g., fluoxetine): EULAR lists fluoxetine as an alternative for patients who can't tolerate vasodilators. That an antidepressant appears on this list highlights just how limited the conventional options are.
• Topical nitroglycerin (1–2%): Applied directly to affected fingers. A 2025 study also found that 2% isosorbide cream was effective and safe in scleroderma patients with digital ulcers, signaling growing interest in topical delivery of vasodilators.
• Endothelin receptor antagonists (e.g., bosentan): Used specifically for preventing new digital ulcers in severe secondary RP, not for general Raynaud's management.

The breadth of this list might seem reassuring at first glance. Each option, however, comes with its own side effect profile, access challenges, and limited evidence base. The common thread is that every single one was designed for a different condition entirely.

Drug-Induced Raynaud's: When Your Other Medications Are the Problem

Certain common medications can trigger or worsen Raynaud's phenomenon, a connection that rarely gets discussed. A 2025 study published in Scientific Reports, using FDA adverse event data, confirmed that multiple drug classes are associated with RP onset or worsening.

The culprits include beta-blockers (commonly prescribed for heart conditions and anxiety), chemotherapy agents, ADHD stimulant medications like amphetamines, and CGRP inhibitors used for migraine prevention. These drugs cause or amplify vasoconstriction, directly provoking the kind of blood vessel spasm that defines a Raynaud's attack.

This matters practically because a patient may be actively managing RP while unknowingly taking a medication that is making it worse. If your Raynaud's symptoms have intensified without an obvious explanation, reviewing your full medication list with your prescriber is a worthwhile step. This connection is almost entirely absent from consumer-facing RP content, so if you've noticed unexplained worsening, you're not imagining things.

Surgical and Interventional Options for Severe Cases

Sympathectomy involves blocking or cutting the nerves near affected blood vessels to reduce vasospasm. It can provide meaningful relief, but the effect typically lasts only one to two years before symptoms recur, which limits its long-term value for most patients.

Fat grafting is a newer approach where fat is injected into the affected hand to promote new vascular formation. It's less established but emerging in clinical practice as an option worth watching.

Botulinum toxin (Botox) injections into the interdigital spaces can block nerve-mediated vasoconstriction. Multiple rounds may be needed before improvement is seen, and the procedure is generally reserved for cases that haven't responded to pharmacological treatment.

A notable gap exists across all of these interventional approaches: none of them, and no major guideline, addresses pain management as a distinct treatment goal. A December 2025 peer-reviewed paper in Arthritis Care & Research explicitly identified this blind spot. For patients whose primary burden is pain rather than attack frequency, current options leave a great deal unaddressed.

There's also a broader health dimension worth noting. Research published in August 2025 found that individuals under 45 with Raynaud's phenomenon had a hazard ratio of 1.23 (95% CI: 1.07–1.42) for major adverse cardiovascular events and 1.32 (95% CI: 1.20–1.46) for venous thromboembolism compared to matched controls, even without underlying autoimmune disease. This reframes Raynaud's from a "nuisance condition" to a potential marker of broader vascular risk, underscoring why comprehensive management matters.

Understanding the Limits of Conventional Care — and What Comes Next

The honest picture is this: conventional treatment for Raynaud's syndrome is stepwise but imperfect. No FDA-approved drug exists. Most medications carry side effects that limit their use, particularly for people with low blood pressure. Surgical options offer only temporary relief. And pain management remains largely unaddressed by clinical guidelines.

For many patients, especially those with primary Raynaud's, medication sensitivities, or blood pressure concerns, conventional options may be inaccessible or insufficient. The fact that only 32% of RP patients ever discuss symptoms with a doctor reflects how many people manage this condition quietly, often feeling dismissed or underserved by the healthcare system.

We understand that experience firsthand. Tamed Organics was founded by someone who lives with Raynaud's, and that personal understanding is why we developed our Raynaud's Symptom Relief Cream – Natural Topical Formula: a plant-based, topical formula designed to complement (not replace) your medical care. For those curious about natural, topical approaches, it's one more option worth exploring alongside the conventional treatments described here.

Understanding the full treatment landscape, including its gaps, puts you in a stronger position to have informed conversations with your healthcare provider. You deserve a management plan that fits your body, your symptoms, and your life.